drugset / Trial / NCT03602833
Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma
Phase 1/2
Completed
12 enrolled
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of this trial is to assess the safety and tolerability of combining compound 451238 and radiotherapy, treating advanced STS.
Timeline
- Start
- 2018-11-05
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Compound 451238 | Unknown | 10 mg/kg | Intravenous |